Navigation Links
BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults
Date:6/29/2015

NESS ZIONA, Israel, June 29, 2015 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary results from its BVX-006 Phase II clinical trial of M-001, BiondVax's candidate for a universal influenza vaccine. In this trial, M-001 was injected intramuscularly to volunteers between the ages of 50 to 65, followed by an administration of the 2014/15 season trivalent influenza vaccine (TIV) 3 weeks later. M-001 was found to be safe and well tolerated and induced humoral immune responses, successfully meeting the primary safety and secondary immunogenicity endpoints.

M-001 in a 1mg dose, primed for immune responses in a manner consistent with previous data in this age group, confirming BiondVax's approach to the development of a universal influenza vaccine. Furthermore, as demonstrated in previous tests, a broadening of the immune response to elicit responses against strains not included in the standard influenza vaccine was detected.

M-001 also elevated the immune response to other strains which were not included in the current influenza seasonal vaccine including against the drifted H3N2 strain of influenza that has caused this year's epidemic in the United States. These results support BiondVax's claim that M-001 provides a broadened and improved coverage against multiple influenza type A and B virus strains.

In addition, the excellent safety profile demonstrated for the 1 mg dose of M-001 will enable BiondVax to safely administer this dose in upcoming trials (such as BVX-007 in Europe). The increased dose is expected to further improve the immune responses against multiple influenza strains when given as a primer or as a standalone product without an adjuvant. Furthermore, the 1mg dose can be particularly beneficial to a population with weakened immunity, such as the elderly.

Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, noted that, "We are very pleased with the results of this trial, which provide us with additional supporting data that our M-001 increases the immune response against multiple flu strains. The results indicating that the 1mg dosage level was well tolerated is very important and these positive results support our continued research and ongoing trials."

Added Dr. Ron Babecoff, BiondVax's President and CEO, "We are very happy with these results, as they demonstrate the importance and value to society of developing M-001. This successful trial brings us one step further towards the phase 3 clinical trial."

About BiondVax Pharmaceuticals Ltd 

BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Forward Looking Statements  

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, uncertainty of clinical preliminary trial results or regulatory approvals or clearances, risks inherent in the development and commercialization of potential products, dependence upon collaborators, adequate resources to undertake and complete the Phase II clinical trials and the success thereof, the market acceptance of our flu vaccine as a broad-coverage solution and adequacy of capital resources for product development and commercialization. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.

For further information, please contact:
Company Contact
Dr Limor Chen, Director of  BD
limor.c@biondvax.com

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
biondvax@gkir.com


'/>"/>
SOURCE Biondvax Pharmaceuticals Ltd
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. BiondVax Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option
2. CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015
3. Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine
4. Developing Human Organs: 3D Bioprinting Presents the Healthcare Sector with Revolutionary Opportunities
5. Takeda Presents Additional Data from Alogliptins EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Associations 75th Scientific Sessions
6. DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO
7. AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting
8. AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting
9. Caris Life Sciences Presents New Tumor Profiling Research Providing Insights into the Clinical Benefit of Targeted Therapies for Colorectal Cancer Treatment-Resistant Subgroups
10. DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme
11. Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2019)... ... 2019 , ... Lake Minnetonka Orthodontics, with locations in Minnetonka, ... Hybrid-Responsive™ website: https://www.lakeminnetonkaortho.com . , The staff of Lake Minnetonka Orthodontics ... with the practice more easily online. Improvements include increased usability, online scheduling, and ...
(Date:9/18/2019)... , ... September 18, 2019 , ... The interns of ... all attended the Youth Consultation Services Foundation (YCS) in Hackensack , where NJ ... spent time with the children and threw them a pizza party and handed out ...
(Date:9/17/2019)... AUCKLAND, New Zealand (PRWEB) , ... September 17, 2019 , ... ... Mention in in Fast Company’s 2019 Innovation by Design Awards Students category. , It ... Lab at the Auckland Bioengineering Institute. , Muss-Bits is comprised of two parts. A ...
Breaking Medicine Technology:
(Date:9/17/2019)... BROOKFIELD, Wis. (PRWEB) , ... September 17, 2019 , ... Milwaukee-area dealership Hall Cars has ... have been affected by cancer. The event, entitled “Drive Out Cancer,” entails that for every ... This Time Tomorrow Foundation. As the event lasts for 50 days, it has also been ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... for Europe and the 21st Century Cures Act in the US, Nocimed has ... and pain management. Using images from existing MRI equipment to perform MR ...
(Date:9/17/2019)... ... September 17, 2019 , ... Drs. Charles Felts and ... teeth in Chattanooga, TN for customized full mouth dental implants with TeethXpress® ... one day, providing a permanent tooth replacement solution for patients who struggle with ...
(Date:9/17/2019)... ... ... Lubin Austermuehle, P.C. will be one of the sponsors of GRIN2B ... Found Kitchen and Social House in Evanston on Monday, October 7 from 6 p.m. ... rare condition that results from changes to the GRIN2B gene. The GRIN2B gene is ...
(Date:9/17/2019)... ... September 17, 2019 , ... Genomenon ... with the goal of providing resources to assist researchers and encourage pharmaceutical companies ... disease causing abnormal iron deposits in the brain. , BPAN Warriors is ...
Breaking Medicine News(10 mins):